Apparatus and methods for mitigation and control of inflammatory responses during usage of an implantable sensor device. In one exemplary embodiment, the implantable sensor device includes a drug-eluting component configured to release a varying amount of anti-inflammatory substance(s) (such as corticosteroid) over the lifetime of the implant, such as according to a desired elution profile. In one variant, this component is also an analyte-permeable membrane used as part of a detector of the implant. Inhibition of inflammation in the tissue improves availability of analytes (such as oxygen and glucose) to the sensor in addition to reducing fibrous encapsulation. Various modifications to the elution rate, and configuration of the implant, allow optimized control over undesirable effects such as foreign body reactions (FBR) or other inflammatory responses which may reduce usable implant lifetime.

NADP-dependent oxidoreductase compositions, and electrodes, sensors and systems that include the same. Analyte sensors include an electrode having a sensing layer disposed thereon, the sensing layer comprising a polymer and an enzyme composition distributed therein. The enzyme composition includes nicotinamide adenine dinucleotide phosphate (NAD(P).sup.+) or derivative thereof; an NAD(P).sup.+-dependent dehydrogenase; an NAD(P)H oxidoreductase; and an electron transfer agent comprising a transition metal complex.

A device for determining a glucose level of a patient includes a set of electrodes comprising a first working electrode, a second working electrode, a counter electrode, and a reference electrode. The reference electrode is electrically coupled to the counter electrode. The device further includes a memory and one or more processors implemented in circuitry and in communication with the memory. The one or more processors configured to determine a sensor signal based on current flowing between the first working electrode and the counter electrode and determine an open circuit potential (OCP) signal based on a voltage across the second working electrode and the reference electrode. The one or more processors are further configured to determine the glucose level of the patient based on the sensor signal and the OCP signal and output an indication of the glucose level.

A medical device communication system with a modular design to communicate with different types of medical devices, such as physiological sensors. The modular design is implemented using an extensible software library that provides a uniform framework for various applications or third party applications access to medical device data. The modular design also allows for regulated and unregulated portions of the system to be integrated into the system while allowing each portion to be updated separately. The regulated portion of the system may include components, such as sensors and the software library, that are subject to regulatory approval while the unregulated portion may include applications that are not subject to regulatory approval. Thus, the system enables a third party application developer to avoid having to submit the application to a regulatory agency for an application making use of the sensor data.

Devices, systems, and methods are provided herein for delivering medication (e.g., insulin) via a wearable pump having a patch-style form factor for adhesion to a user's body. The reusable pump may be coupled to a disposable cap housing a microdosing system for delivering precise, repeatable doses of medication to a cannula configured to deliver medication to a target infusion area beneath the user's outer skin layer. The system further may include an applicator for inserting the cannula into the user's skin and/or applying an adhesive pad to the skin.

A device for continuously monitoring glucose levels in a patient is disclosed. The device includes a glucose electronics assembly and a glucose lead assembly in electrical communication with the glucose electronics assembly. The glucose electronics assembly is configured to be positioned in the subcutaneous tissue and the glucose lead assembly is configured to be positioned in a vessel of the patient. The glucose lead assembly has a central shaft, a first electrode in physical communication with the central shaft, a second electrode in physical communication with the central shaft, a third electrode in physical communication with the central shaft and a positioning element configured to have an undeployed state and a deployed state. In the undeployed state, the positioning element is substantially linear, and in the deployed state, the positioning element extends away from the central shaft.

Systems for applying a transcutaneous monitor to a person can include a telescoping assembly, a sensor, and a base with adhesive to couple the sensor to skin. The sensor can be located within the telescoping assembly while the base protrudes from a distal end of the system. The system can be configured to couple the sensor to the base by compressing the telescoping assembly.

A needle member includes: a tubular side wall through which a hollow portion extends in a longitudinal direction. An opening portion connected to the hollow portion extends laterally through the tubular side wall. The tubular side wall comprises a side wall reinforcement portion located at a position opposing the opening portion, wherein the hollow portion is interposed between the opening portion and the side wall reinforcement portion.

The present invention relates generally to devices for measuring an analyte in a host. More particularly, the present invention relates to devices for measurement of glucose in a host that incorporate a cellulosic-based resistance domain.

Devices and methods are provided for continuous measurement of an analyte concentration. The device can include a sensor having a plurality of sensor elements, each having at least one characteristic that is different from other sensor(s) of the device. In some embodiments, the plurality of sensor elements are each tuned to measure a different range of analyte concentration, thereby providing the device with the capability of achieving a substantially consistent level of measurement accuracy across a physiologically relevant range. In other embodiments, the device includes a plurality of sensor elements each tuned to measure during different time periods after insertion or implantation, thereby providing the sensor with the capability to continuously and accurately measure analyte concentrations across a wide range of time periods. For example, a sensor system 180 is provided having a first working electrode 150 comprising a first sensor element 102 and a second working electrode 160 comprising a second sensor element 104, and a reference electrode 108 for providing a reference value for measuring the working electrode potential of the sensor elements 102, 104.